1. Российское медицинское общество по артериальной гипертонии – Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
2. Brown B, Hall A. Renin-angiotensin system: the weight of evidence. Am J Hypertens 2005; 18: 127S–33S.
3. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004.
4. Dahlo..f B, Devereux RB, Kjeldsen SE. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
5. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.
6. Ogihara T, Fujimoto A, Nakao K, Saruta T; CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
7. Lindholm L, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.
8. Okin PM, Devereux RB, Gerdts E et al. LIFE Study Investigators. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006; 113 (12): 1588–96.
9. Gerdts E, Okin PM, Omvik P et al. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr Metab Cardiovasc Dis 2009; 19 (5): 306–12.
10. de Simone G, Okin PM, Gerdts E et al. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis 2009; 20 (6): 432–7.
11. Okin PM, Devereux RB, Harris KE et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2007; 50 (5): 984–90.
12. Okin PM, Devereux RB, Jern S et al. LIFE Study Investigators Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292 (19): 2343–9.
13. Okin PM, Devereux RB, Harris KE et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007; 147 (5): 311–9.
14. Okin PM, Oikarinen L, Viitasalo M et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation 2009; 119 (14): 1883–91.
15. Oikarinen L, Nieminen MS, Viitasalo M et al. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2004; 43 (5): 1029–34.
16. Olsen MH, Wachtell K, Ibsen H et al. LIFE Study Investigators Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24 (4): 775–81.
17. Okin PM, Wachtell K, Devereux RB et al. LIFE Study Investigators. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. Am J Hypertens 2008; 21 (3): 273-9.
18. Kjeldsen SE, Dahlo..f B, Devereux RB et al. LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288 (12): 1491–8.
19. Os I, Franco V, Kjeldsen SE et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008; 51 (4): 1103–8.
20. Devereux RB, Dahlo..f B, Kjeldsen SE et al. LIFE Study Group. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med 2003; 139 (3): 169–77.
21. Franklin SS, Wachtell K, Papademetriou V et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 2005; 46 (3): 492–9.
22. Fossum E, Moan A, Kjeldsen SE et al. LIFE Study Group. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 46 (5): 770–5.
23. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45 (5): 712–9.
24. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45 (11): 1832–9.
25. Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45 (5): 705–11.
26. Boersma C, Carides GW, Atthobari J et al. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. Clin Ther 2007; 29 (5): 963–71.
27. Mogensen CE. The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 2001; 37: S2–6.
28. Дедов И.И., Шестакова М.В. Диабетическая нефропатия. М.: Универсум паблишинг, 2000.
29. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861–9.
30. Appel GB, Radhakrishnan J, Avram MM et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26 (5): 1402–7.
31. Winkelmayer WC, Zhang Z, Shahinfar S et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006; 29 (10): 2210–7.
32. Bakris GL, Weir MR, Shanifar S et al. RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163 (13): 1555–65.
33. Boner G, Cooper ME, McCarroll K et al. RENAAL Investigators. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 2005; 48 (10): 1980–7.
34. Carides GW, Shahinfar S, Dasbach EJ et al. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics 2006; 24 (6): 549–58.
35. Remuzzi G, Ruggenenti P, Perna A et al.; RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15 (12): 3117–25.
36. Carr AA, Kowey PR, Devereux RB et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005; 96 (11): 1530–6.